Loading...
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Eltrombopag, an oral thrombopoietin receptor agonist, is dosed daily to treat chronic immune thrombocytopenia (ITP). As it has a half‐life of 26–35 h in ITP patients and requires patents to abide by strict dietary restrictions that may impair quality of life and reduce compliance, we developed an al...
Na minha lista:
| Udgivet i: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6177710/ https://ncbi.nlm.nih.gov/pubmed/30032487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13717 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|